CD44v6: a target for antibody-based cancer therapy

Area of Science:

• Molecular biology
• Immunology
• Oncology

Background:

• The CD44 gene encodes transmembrane glycoproteins crucial for cell interactions.
• Alternative splicing of CD44 exons generates diverse protein isoforms, including CD44 variant domain 6 (CD44v6).
• CD44v6 is linked to tumor development, invasion, and metastasis.

Purpose of the Study:

• To provide an overview of CD44v6 expression in human malignancies and normal tissues using immunohistochemistry.
• To review the clinical applications of CD44v6-specific antibodies.
• To assess CD44v6 as a therapeutic target in epithelial cancers.

Main Methods:

• Immunohistochemical analysis of CD44v6 expression.
• Review of clinical data on CD44v6-specific antibody applications.
• Comparison of CD44v6 expression in malignant versus nonmalignant tissues.

Main Results:

• CD44v6 expression is largely restricted to a subset of epithelia in nonmalignant tissues.
• Intense and homogeneous CD44v6 expression is prevalent in most squamous cell carcinomas and some adenocarcinomas.
• CD44v6 expression is infrequent in nonepithelial tumors.

Conclusions:

• The distinct expression pattern of CD44v6 in epithelial cancers versus normal tissues supports its role as a potential therapeutic target.
• CD44v6-specific antibodies show promise for targeted therapy in epithelium-derived cancers.
• Further clinical evaluation of CD44v6-targeted therapies is warranted.